NCI-H69/LX20

96042332, human lung, Not specified

• UNSPSC-Code: 41106514

Eigenschaften

• product name: NCI-H69/LX20, 96042332
• Biologische Quelle: human lung
• Wachstumsmodus: Aggregates in suspension
• Karyotyp: Not specified
• Morphologie: Not specified
• Produkte: Not specified
• Rezeptoren: Not specified
• Methode(n): cell culture | mammalian: suitable
• Relevante Krankheit(en): cancer
• Versandbedingung: dry ice
• Lagertemp.: −196°C

Beschreibung

Ursprung der Zelllinie

Human Caucasian small cell lung carcinoma

Beschreibung der Zelllinie

The drug-resistant cell line NCI-H69/LX20 has been derived by exposure of the parent line, H69 (ECACC Number 91091802) to doxorubicin, also known as adriamycin. These multi drug resistant (MDR) cells have been found to be recognised by various anti-P-glycoprotein antibodies.

Anwendung

Analysis of acquired drug resistance, study of small cell lung carcinoma, MDR studies.

Nährmedium

RPMI 1640 + 2mM Glutamine + 2μg/ml Doxorubicin + 10% Foetal Bovine Serum (FBS). ECACC has found that the following supplement will assist good growth of cells: sodium selenite 10nM, Insulin 250ng/ml, Transferrin 10ug/ml and sodium pyruvate 1mM.

Subkultur-Routine

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO₂; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage. Resuscitate into 9 ml of medium. Immediately after resuscitation perform a centrifugation ste

Sonstige Hinweise

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.